 In this study, we investigated the effectiveness of the BNT-162B2 mRNA SARS-CoV-2 vaccine in individuals with sarcoidosis compared to healthy controls. Our results showed that subjects with sarcoidosis have similar antibody responses to the vaccine as healthy controls, suggesting that they may be protected from infection. Additionally, our findings suggest that the antibodies produced by the vaccine persist over time in the sarcoidosis population. Further studies should investigate the role of other antibody types and their potential protective effects against infection. This article was authored by Crissen L. Wacht, Yixin Chang, Christian Ascoli, and others.